Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome
JCI Insight · 2025
DOI: 10.1172/jci.insight.188014 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Sheng Tang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: NAV1.1 Voltage-Gated Sodium Channel, Epilepsies, Myoclonic, Oligonucleotides, Antisense, Exons. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NICHD NIH HHS, NINDS.
Abstract (Originalsprache)
Dravet syndrome is a developmental and epileptic encephalopathy associated with pathogenic variants in SCN1A. Most disease-causing variants are located within coding regions, but recent work has shed light on the role of noncoding variants associated with a poison exon in intron 20 of SCN1A. Discovery of the SCN1A poison exon known as 20N has led to the first potential disease-modifying therapy for Dravet syndrome in the form of an antisense oligonucleotide. Here, we demonstrate the existence of 2 additional poison exons in introns 1 and 22 of SCN1A through targeted, deep-coverage long-read sequencing of SCN1A transcripts. We show that inclusion of these poison exons is developmentally regulated in the human brain, and that deep intronic variants associated with these poison exons lead to their aberrant inclusion in vitro in a minigene assay or in iPSC-derived neurons. Additionally, we show that splice-modulating antisense oligonucleotides can ameliorate aberrant inclusion of poison exons. Our findings highlight the role of deep intronic pathogenic variants in disease and provide additional therapeutic targets for precision medicine in Dravet syndrome and other SCN1A-related disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
- Translational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium.
- Department of Neurology, Antwerp University Hospital, Antwerp, Belgium.
Förderung
- NINDS NIH HHS
- NICHD NIH HHS
- NINDS
- NICHD
Zitieren
APA
Tang, S., Stamberger, H., Calhoun, J. D., Weckhuysen, S., & Carvill, G. L. (2025). Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome. JCI Insight. https://doi.org/10.1172/jci.insight.188014
Vancouver
Tang S, Stamberger H, Calhoun JD, Weckhuysen S, Carvill GL. Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome. JCI Insight. 2025. doi:10.1172/jci.insight.188014
BibTeX
@article{Tang2025,
author = {Tang, Sheng and Stamberger, Hannah and Calhoun, Jeffrey D and Weckhuysen, Sarah and Carvill, Gemma L},
title = {Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome},
journal = {JCI Insight},
year = {2025},
doi = {10.1172/jci.insight.188014}
}
EUVIMED